The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Compounding Chemotherapy Market Compare Between 2026 And 2030?
The compounding chemotherapy market size has experienced substantial growth over recent years. It is anticipated to expand from $6.11 billion in 2025 to $6.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. This historical growth can be ascribed to several factors, including the constrained availability of compounding technologies, the rising prevalence of cancer, reliance on hospital-based compounding practices, increasing understanding of cytotoxic drug safety, and the adoption of manual preparation techniques.
The compounding chemotherapy market is projected to experience robust expansion over the coming years, with its size anticipated to reach $8.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This growth during the forecast period is primarily driven by factors such as the development of automated and robotic compounding systems, the increasing availability of homecare chemotherapy services, a rise in investment toward sterile pharmacy infrastructure, enhanced regulatory compliance for personalized medicine, and the growth in targeted therapies and immunomodulatory agents. Significant trends expected during this period include the rising adoption of personalized chemotherapy formulations, the integration of robotic compounding systems, the expansion of compounding services to homecare settings and specialty clinics, a greater focus on sterile and contamination-free environments, and an increased demand for supportive care drug compounding.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp
Which Major Drivers Are Influencing The Expansion Of The Compounding Chemotherapy Market?
The anticipated surge in cancer diagnoses is projected to fuel the expansion of the compounding chemotherapy market in the foreseeable future. Cancer is characterized as a group of diseases involving the uncontrolled proliferation and spread of abnormal cells throughout the body. The escalating incidence of cancer cases primarily results from unhealthy lifestyles, including poor diet, lack of physical activity, smoking, excessive alcohol consumption, and prolonged exposure to environmental pollutants, all of which significantly heighten the risk of various cancer types. Compounding chemotherapy aids cancer treatment by enabling personalized medication formulations specifically tailored to individual patient requirements, thereby enhancing efficacy and minimizing adverse effects. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents 8,605 more than in 2022. Consequently, the rising prevalence of cancer cases is a key driver for the growth of the compounding chemotherapy market.
What Are The Different Segment Types In The Compounding Chemotherapy Market Segment Breakdown?
The compounding chemotherapy market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs
What Trends Are Influencing The Evolution Of The Compounding Chemotherapy Market?
Companies operating within the compounding chemotherapy market are focusing on developing innovative solutions, such as robotic chemotherapy automation systems, to enhance the accuracy, safety, and efficiency of preparing personalized cancer treatments. These advanced machines, known as robotic chemotherapy automation systems, are designed to precisely and securely prepare personalized chemotherapy doses by automating the compounding process, thereby reducing human error and contamination risks. For instance, in February 2024, Simplivia Healthcare Ltd., an Israel-based healthcare technology company, launched Smart Compounders Advanced Systems to automate and streamline the preparation of cytotoxic (chemotherapy) drugs. These systems handle the compounding of cytostatics and antibodies with a capacity of 20 to 40 preparations per hour, incorporating automatic gravimetric verification and documentation to ensure high accuracy. They significantly minimize pharmacy staff’s exposure to hazardous substances and are designed to integrate effortlessly into existing laminar airflow (LAF) cabinets or isolators without requiring any modifications.
Who Are The Well-Known Companies In The Compounding Chemotherapy Market?
Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.
Get The Full Compounding Chemotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report
Which Region Has The Greatest Market Share In The Compounding Chemotherapy Market?
North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Compounding Chemotherapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report
Browse Through More Reports Similar to the Global Compounding Chemotherapy Market 2026, By The Business Research Company
Chemotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model